(SWKH) SWK Holdings - Ratings and Ratios

SWK Holdings Corporation (NASDAQ:SWKH) is a specialized finance and asset management company operating in the United States. The firm is structured into two primary segments: Finance Receivables and Pharmaceutical Development. The Finance Receivables division specializes in providing tailored financing solutions to life science companies, including biotechnology firms, medical device manufacturers, and pharmaceutical enterprises. It also offers non-discretionary investment advisory services to institutional clients, focusing on life science finance opportunities. The Pharmaceutical Development segment provides drug development, formulation, and manufacturing services, leveraging proprietary technologies such as the Peptelligence platform for oral drug delivery. Additionally, the company engages in intellectual property licensing.

Formerly known as Kana Software, Inc., SWK Holdings Corporation rebranded in December 2009. Established in 1996, the company is headquartered in Dallas, Texas, and maintains a market capitalization of $207.96M USD. Its stock trades on the NASDAQ under the ticker symbol SWKH, classified under the Specialized Finance sub-industry. The company’s current price-to-earnings ratio stands at 20.24, with a price-to-book ratio of 0.74 and a price-to-sales ratio of 8.41. Return on equity is reported at 4.08.

As of the latest data, SWKH’s average 20-day trading volume is 6,588 shares, with a last recorded price of $16.62. The stock’s short-term moving averages indicate a 20-day SMA of $16.80 and a 50-day SMA of $16.45, while the 200-day SMA is $16.77. The Average True Range (ATR) is 0.34, reflecting moderate price volatility.